Keros Therapeutics (KROS) Research & Development (2019 - 2025)

Keros Therapeutics has reported Research & Development for 7 years, with the latest figure at $17.9 million in Q4 2025.

• For the quarter ending Q4 2025, Research & Development fell 60.75% year-over-year to $17.9 million; the trailing twelve-month figure through Dec 2025 stood at $129.6 million (down 25.33% YoY), and the FY2025 full-year result was $129.6 million, down 25.33% from the prior year.
• Research & Development for Q4 2025 stood at $17.9 million, down from $19.5 million in the prior quarter.
• The five-year high for Research & Development was $49.2 million in Q3 2024, with the low at $10.0 million in Q2 2021.
• Historically, Research & Development has averaged $29.0 million across 5 years, with a median of $28.0 million in 2022.
• Annual changes were most pronounced in 2022 — Research & Development surged 133.21% — and 2025, when it tumbled 60.75%.
• Keros Therapeutics' Research & Development stood at $18.8 million in 2021, then surged by 32.04% to $24.9 million in 2022, then jumped by 50.77% to $37.5 million in 2023, then grew by 21.71% to $45.6 million in 2024, then plunged by 60.75% to $17.9 million in 2025.
• The last three Research & Development figures came in at $17.9 million (Q4 2025), $19.5 million (Q3 2025), and $43.5 million (Q2 2025), per Business Quant data.